2.09

0.48% 0.010

After Hours: 2.07 -0.02 -0.96%

Acrivon Therapeutics Inc (ACRV)

Overview News Price History Financials Discussions Forecast

Acrivon Therapeutics Inc stock is traded at $2.09, with a volume of 423.38K. It is up +0.48% in the last 24 hours and up +33.12% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Previous Close:

$2.08

Open:

$2.11

24h Volume:

423.38K

Relative Volume:

0.52

Market Cap:

$89.45M

Revenue:

Net Income/Loss:

$-77.91M

P/E Ratio:

-1.0329

EPS:

-2.0234

Net Cash Flow:

$-65.33M

1W Performance:

+15.47%

1M Performance:

+33.12%

6M Performance:

+4.50%

1Y Performance:

+57.14%

1-Day Range:

$2.04

$2.14

1-Week Range:

$1.79

$2.24

52-Week Range:

$1.05

$3.56

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name

Acrivon Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-207-8979

Address

480 ARSENAL WAY, SUITE 100, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

ACRV's Discussions on Twitter

Compare ACRV vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRV Acrivon Therapeutics Inc	2.09	89.03M	0	-77.91M	-65.33M	-2.0234
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-05-25	Resumed	Piper Sandler	Overweight
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform
Dec-15-23	Resumed	Jefferies	Buy
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform
May-08-23	Initiated	BMO Capital Markets	Outperform
Apr-27-23	Initiated	Ladenburg Thalmann	Buy
Apr-20-23	Initiated	H.C. Wainwright	Buy
Dec-12-22	Initiated	Cowen	Outperform
Dec-12-22	Initiated	Jefferies	Buy
Dec-12-22	Initiated	Piper Sandler	Overweight

View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

Apr 30, 2026

Acrivon Therapeutics (NASDAQ: ACRV) sets 2026 virtual meeting, director and auditor votes - Stock Titan

Apr 30, 2026

Apr 27, 2026

Acrivon Therapeutics shares slide sharply following mixed oncology trial update - MSN

Apr 27, 2026

Apr 24, 2026